Macrogen Selects N-of-One to Provide Patient-specific Interpretation for the Launch of New Clinical Next-Generation Sequencing Panels
- Posted by Emily Haynes
- On April 5, 2016
- 0 Comments
LEXINGTON, Mass., April 5, 2016 – N-of-One, Inc., the leader in clinical interpretation, providing patient-specific therapeutic options for precision medicine in oncology, today announced that Macrogen Corp. has selected N-of-One to provide high-quality clinical interpretation for its newly launched clinical next-generation sequencing (NGS) panels used for cancer patients. Financial terms of the agreement are not disclosed.
Macrogen Corp. is a CLIA certified laboratory that offers sequencing-based genomic testing services to North American hospitals and patients. The genomic tests showcase highly advanced DNA screenings that identify specific genes and genetic mutations in a patient’s genome that are related to major cancers and genetic diseases. The use of Next Generation Sequencing technology makes it possible to process, sequence, and analyze large volumes of genes and long strands of genetic code, thereby allowing individualized treatment plans to be accessible.
N-of-One’s patient-specific analysis identifies therapeutic options based on each patient’s specific molecular profile identified by the sequencing data. These therapeutic options include therapies in guidelines, off label therapies, and the most relevant clinical trials prioritized based on molecular and geographical relevance.
“The partnership between Macrogen and N-of-One will further strengthen Macrogen’s growth in the clinical setting to enable accessibility of personalized medicine,” said Sang Tae Park, Ph.D., the CEO of Macrogen Corp. “It will deliver comprehensive and clear reports including therapeutic options suited to each patient with information of molecular/clinical relevance and eligible clinical trials for the rapidly growing number of clinical cancer NGS test results.”
“N-of-One is very pleased to partner with Macrogen, supporting their goal of delivering the highest quality report at a cost effective price”, said Chris Cournoyer, CEO at N-of-One.
Macrogen Corp. (Rockville, MD), established in 2005, also shares two decades of experience of Macrogen Inc. (Seoul, Korea) in top-quality genomic sequencing. With its origins of Korea, Macrogen is continually expanding both globally and with the services that it provides, including the launching of CLIA-certified services in 2012.
Macrogen strives to provide the absolute best quality results at the fastest possible turnaround time by constantly adapting to cutting-edge technologies and evolving sequencing platforms. The technology coupled with the invaluable knowledge and expertise, now empowered further by the capability to serve both researchers and clinicians, allows Macrogen to be the world leading service provider. For more information, please visit http://www.macrogenlab.com.
N-of-One, the leader in clinical interpretation, providing patient-specific therapeutic options for precision medicine in oncology, leverages its world-class team of practicing oncologists and Ph.D. scientists, coupled with proprietary technology and processes, to enable laboratories to save time and money while scaling their molecular diagnostics programs. N-of-One’s team of experts has provided therapeutic options to client organizations for thousands of patient cases across hundreds of cancer types. N-of-One partners with leading diagnostic companies and hospital systems. N-of-One does not provide medical services, nor is any N-of-One employee engaged in the practice of medicine for or on behalf of N-of-One. For more information, please visit www.n-of-one.com or call 617-202-9808.